Current Report Filing (8-k)
June 07 2016 - 9:35AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): June 7, 2016
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified
in its charter)
|
|
|
|
|
Delaware
|
|
001-33357
|
|
65-0643773
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
2 Snunit Street
|
|
20100
|
Science Park, POB 455
|
|
|
Carmiel, Israel
|
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant's telephone number, including
area code +972-4-988-9488
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01. Regulation FD Disclosure
On June 7, 2016, Moshe Manor, the President and Chief Executive
Officer of Protalix BioTherapeutics, Inc., presented a corporate overview at the Jefferies 2016 Global Healthcare Conference. A
copy of the slide presentation used in Mr. Manor’s presentation is attached hereto as Exhibit 99.1 and is incorporated by
reference herein.
An archived webcast of the presentation is available at www.protalix.com,
on the event calendar page.
All of the information furnished in Item 7.01 and Exhibit
99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended, and unless expressly set forth by specific reference in such filings, shall not be incorporated by reference in any
filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general
incorporation language in such filings.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
99.1 Slide Presentation entitled “Protalix BioTherapeutics
Corporate Update – June 2016.”
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PROTALIX BIOTHERAPEUTICS, INC.
|
|
|
Date: June 7, 2016
|
By:
/s/ Moshe Manor
|
|
Name: Moshe Manor
|
|
Title: President and Chief Executive Officer
|
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Sep 2023 to Sep 2024